Briefing: Developing an Approval Pathway for Limited-Population Antibacterial Drugs

Briefing: Developing an Approval Pathway for Limited-Population Antibacterial Drugs

On July 28th, The Pew Charitable Trusts, the Infectious Diseases Society of America, and Trust for America’s Health co-sponsored a briefing with a panel of antibacterial drug experts and stakeholders to discuss the development of a limited-population antibacterial drug (LPAD) approval pathway. Bipartisan legislation has been approved by the House of Representatives and introduced in the Senate: the Promise for Antibiotics and Therapeutics for Health (PATH) Act, S. 185.

The LPAD pathway would enable the approval of new antibiotics that target serious or life-threatening drug-resistant infections in patients who have few or no suitable treatment options. LPAD could help bring critical new drugs to such patients, limiting their use to targeted populations while maintaining safety and efficacy standards and requiring post-market surveillance.

The briefing included presentations, discussion, and an interactive question-and-answer session. 

Expert Panel

  • Janet Woodcock, MD, Director, FDA’s Center for Drug Evaluation and Research
  • Helen Boucher, MD, Associate Professor, Tufts University School of Medicine; Member, IDSA Antimicrobial Resistance Committee
  • Prabhavathi Fernandes, PhD, President and Chief Executive Officer, Cempra Pharmaceuticals
  • Allan Coukell, Senior Director for Health Programs, the Pew Charitable Trusts (moderator) 

Slides

Spotlight on Mental Health

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies

Explore

Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.